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Abstract 
Imatinib (Gleevec/Glivec) has demonstrated high and durable hematologic and 
cytogenetic response rates, favorable safety and toxicity profiles, and prolonged survival 
when used for the treatment of chronic myeloid leukemia (CML). Imatinib copy drugs are 
currently available in some countries; however, the safety and efficacy of these 
compounds have not been widely assessed. We present a patient who received the copy 
drug imatinib-COPER, lost hematologic response while on therapy, and was 
subsequently treated with branded Glivec. This report, and other published cases, 
suggests that imatinib copy drugs may not be equivalent to branded Glivec in 
pharmacology, safety, and efficacy. The case was a 42-year-old Moroccan male with CML. 
Initial therapy with hydroxyurea alone followed by hydroxyurea in combination with 
interferon-α resulted in durable complete hematologic remission (CHR). Due to adverse 
effects, the patient was switched to imatinib-COPER at 400 mg/day. Despite compliance 
with therapy, he lost his CHR after 2 years and presented with aplasia requiring a blood 
transfusion. Administration of Glivec in combination with hydroxyurea resulted in 
re-achievement of complete hematologic remission that was stable at last follow-up. 
Data from large-scale trials demonstrating high and durable responses and favorable 
safety have resulted in Glivec being considered as standard frontline therapy for patients 
with CML. Such trials have not been conducted for imatinib copy drugs. In the absence of 
clinical trial data, information from individual cases is critical to assessing the utility of 
copy drugs. This report suggests that initial treatment with an imatinib copy drug may 
compromise efficacy.  
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Introduction 
Imatinib mesylate (Glivec/Gleevec; Novartis Pharmaceuticals Corporation), an 
inhibitor of the constitutively active oncogenic fusion protein tyrosine kinase BCR-ABL 
[1, 2], is the recommended frontline treatment for all patients with chronic myeloid 
leukemia (CML) [3, 4]. The International Randomized Study of Interferon and STI571 
(IRIS) trial demonstrated improved safety and efficacy over the previous standard of care, 
interferon-α plus cytarabine [5]. Long-term follow-up from the IRIS trial at 7 years 
demonstrated a cumulative best complete cytogenetic response (CCyR) rate of 82% in 
patients randomized to imatinib [6]. At 7 years, 93% of patients had freedom from 
progression to accelerated phase/blast crisis, and the event-free and overall survival rates 
were 81 and 86%, respectively.  
Although Glivec has been clinically proven to induce durable responses [5–8], to 
prolong survival [6–8], and to have a favorable long-term safety profile [6–8], some 
patients look for substitutes due to cost or lack of access. In several countries, alternative, 
lower-cost ‘copies’ of Glivec are available. While these products are marketed as being 
comparable to Glivec, little is known about the relative efficacy or safety of these products. 
Bio- and pharmaceutical equivalence to Glivec has not been established, and these agents 
have not been evaluated in randomized clinical trials. Thus, the question of whether use 
of Glivec ‘copies’ may result in compromised patient safety and treatment outcomes 
remains unanswered. 
Here, we report a case of a patient diagnosed with CML in chronic phase (CML-CP) 
treated in Morocco, who was originally treated with hydroxyurea/interferon-α and 
subsequently with the Glivec copy ‘imatinib-COPER,’ then switched to branded Glivec 
after experiencing hematologic relapse on the copy drug.  
Case Presentation 
In May 2002, a 42-year-old male was diagnosed with CML during a routine checkup. He exhibited 
no splenomegaly, but had ganglions and adenopathies of the lateroinguinal and cervical lymph nodes of 
a few millimeters. The patient was otherwise healthy and had no significant medical or surgical history. 
Initial laboratory assessment revealed a total leukocyte count of 207,000/mm
3, hemoglobin 
concentration of 10.7 g/dl, and 18% blast cells in the peripheral blood smear (table 1). A diagnosis of 
CML-CP was confirmed by fluorescence in situ hybridization (FISH) analysis of a peripheral blood 
specimen, which revealed 100% Philadelphia chromosome-positive (Ph+) cells. 
The patient was treated with hydroxyurea at 3 g/day for 2 months. In July 2002, his total leukocyte 
count had dropped to 3,000/mm
3 and he had achieved complete hematologic response (CHR). He was 
then switched to hydroxyurea at 2 g/day supplemented with subcutaneous interferon-α at a daily target 
dose of 3 million U/m
2 5 days a week until October 2002. At this time, interferon was stopped. One 
month after stopping interferon, the patient remained in CHR. The patient continued on hydroxyurea 
at 2 g/day until April 2004. In June 2005, the patient, who remained in CHR, presented with algic mouth 
ulcers, which led to discontinuation of treatment with hydroxyurea. 
In September 2006, the patient was started on a copy of imatinib called imatinib-COPER at 400 
mg/day. In January 2007, the patient showed a reduction in mouth ulcers, was generally feeling better, 
and was in hematologic remission. In December 2008, after 2 years on therapy, the patient began to feel 
ill and presented with aplasia requiring an urgent blood transfusion. Prior to transfusion, he had a 
decreased hemoglobin level (7.4 g/dl) and lost his CHR (total leukocyte count, 90,960/mm
3). 
Karyotyping of 20 metaphase cells revealed clonal evolution in 2 cells. One Ph+ clone also had trisomy 
8; one clone had a double Ph chromosome and trisomy 8. Imatinib-COPER treatment was immediately 
stopped. The patient reported compliance with daily imatinib-COPER therapy throughout treatment 
(2 years and 3 months total).   
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At this time, the patient was switched to branded Glivec at 400 mg/day in combination with low-
dose (1 g/day) hydroxyurea. The patient achieved complete hematologic remission within 1 month of 
starting Glivec (table 1). After 2 months, he stopped hydroxyurea and remains on Glivec at 400 mg/day. 
His last checkup was September 2009, at which time he had gained weight, returned to work, and 
remained in CHR.  
Conclusion 
The patient described herein achieved CHR on hydroxyurea, but had to end treatment 
due to unmanageable side effects. Two years after switching to the Glivec copy drug 
imatinib-COPER, he lost his hematologic response, and clonal evolution was revealed. 
The patient reported compliance to therapy, and reasons for failure are unknown. Within 
1 month of initiating branded Glivec at 400 mg/day, the patient regained CHR. Thus, 
failure on imatinib-COPER did not result from acquired imatinib resistance. These data 
suggest that imatinib-COPER may be a very different molecular entity from Glivec and 
has substantially different pharmacokinetic and pharmacodynamic characteristics. This is 
likely to result in differences in safety and efficacy between imatinib-COPER and Glivec, 
as was demonstrated in this case.  
While the copy product used to treat this patient was intended to be comparable to 
Glivec, there is no published clinical evidence to support the claim of comparable safety 
or efficacy. In contrast, long-term follow-up from the IRIS trial demonstrates durable 
hematologic, cytogenetic, and molecular responses in the majority of patients treated with 
Glivec [6–8]. At 12 months on therapy, the estimated rates of CHR, major cytogenetic 
response, and CCyR were 96, 85, and 85%, respectively, in patients randomized to 
imatinib, increasing to 98, 92, and 87% at 5 years [7]. Hematologic relapse, as was seen in 
this case, was highly uncommon among patients treated with frontline imatinib on IRIS.  
This case report suggests that initial therapy with an imatinib copy drug may 
compromise efficacy and detrimentally impact long-term outcomes in patients with CML. 
Further studies are needed to confirm this finding. Switching to a copy drug in a patient 
responding to Glivec may similarly compromise outcomes. Major guidelines recommend 
indefinite continuation of imatinib therapy unless loss of response or intolerance occurs 
[3, 4]. 
In an interim analysis of the Stop Imatinib (STIM) discontinuation study, in which 
Glivec was discontinued in patients sustaining complete molecular response for at least 2 
years, 36 of 70 patients (51%) experienced molecular relapse [9]. Other case series have 
shown a similar risk of relapse upon discontinuation of Glivec [10–12]. The impact of 
switching to a copy drug in a similar patient population is unknown. In the absence of 
clinical trials comparing safety and efficacy of Glivec with copies, patients administered 
Glivec copies require careful monitoring and follow-up. 
In cases where medical insurance is limited, treatment cost may be a major factor in 
the decision to prescribe a Glivec copy. To ensure access to the agent currently approved 
throughout the world as frontline therapy for CML, Novartis Pharmaceuticals 
Corporation has established the Glivec International Patent Assistance Program (GIPAP). 
This program, available in more than 80 countries worldwide, is designed to provide 
FDA-approved imatinib to qualified patients. Maintaining daily medication with the 
approved drug and careful monitoring of response and adverse events are crucial for 
ensuring optimal long-term outcomes in patients with CML.  
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Table 1. Hematologic parameters at baseline and following treatment changes 
Baseline Hydroxy- 
urea 
Hydroxyurea/ 
interferon 
On copy drug (imatinib-
COPER) 
At discon-
tinuation of 
copy drug 
After starting imatinib 
(Glivec) 
   
May 2002   July 2002  
(2 months 
on hydroxy-
urea) 
Nov 2002  
(4 months on 
hydroxyurea/
IFN) 
Sept 13, 2006 
(day before 
starting 
treatment) 
Nov 21, 2006 
(2 months 
after 
treatment) 
  Dec 2008  Dec 20, 
2008 
Mar 23, 
2009 
May 6, 
2009 
Red blood cell count,  
×106 n/mm3 
 
3.51 
 
3.90 
 
3.91 
 
2.95 
 
4.01 
  
3.25 
 
3.42 
 
3.41 
 
3.61 
Monocytes, %  10.7  12.4  12.4  12.4  13.8    11.1  11.7  11.9  13.2 
Total leukocyte count, n/mm3 207,000  3,000  11,000  13,500  8,000   90,690  54,000  6,980  7,530 
Neutrophils, %  56  52  70  62  69    45  58  64  54 
Eosinophils, %  1  2  2  2  4    1  .1 7  1 
Basophils, %  1  0  0  0  0    0  1  4  0 
Lymphocytes, %  8  45  23  15  26    4  7  1.6  41 
Monocytes, %  2  1  5  2  1    3  0  8  4 
Platelet count, n/mm
3 unknown  87,000  53,000  239,000  172,000    175,000  162,000  85,000  85,000
Myelemy 42%    04% 
Myeloblasts 18%    47% 
Myelocytes 17%    08% 
Metamyelocytes  07% 
100% –  
no more myelemy 
100% –  
no more myelemy 
 11% 
100% –  
no more myelemy 
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